SPHS stock forecast
Our latest prediction for Sophiris Bio, Inc.'s stock price was made on the Sept. 19, 2018 when the stock price was at 2.68$.
In the short term (2weeks), SPHS's stock price should outperform the market by 6.40%. During that period the price should oscillate between -8.60% and +16.66%.
In the medium term (3months), SPHS's stock price should outperform the market by 7.82%. During that period the price should oscillate between -20.27% and +41.62%.Get email alerts
About Sophiris Bio, Inc.
Sophiris Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products for the treatment of urological diseases. The firm develops PRX302 as a treatment for the symptoms of benign prostatic hyperplasia which is a non cancerous enlargement of the prostate gland that causes a restriction in urine flow from the urethra resulting in lower urinary tract symptoms. The company was founded by James L. Heppell in May 2003 and is headquartered in La Jolla, CA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -0.55$ per share.
The book value per share is -0.04$
Three months stock forecastSept. 19, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|